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Abstract The volume under the receiver operating characteristic surface (VUS)
is useful for measuring the overall accuracy of a diagnostic test when the possi-
ble disease status belongs to one of three ordered categories. In medical studies,
the VUS of a new test is typically estimated through a sample of measure-
ments obtained by some suitable sample of patients. However, in many cases,
only a subset of such patients has the true disease status assessed by a gold
standard test. In this paper, for a continuous-scale diagnostic test, we propose
four estimators of the VUS which accommodate for nonignorable missingness
of the disease status. The estimators are based on a parametric model which
jointly describes both the disease and the verification process. Identifiability of
the model is discussed. Consistency and asymptotic normality of the proposed
estimators are shown, and variance estimation is discussed. The finite-sample
behavior is investigated by means of simulation experiments. An illustration
is provided.
Keywords Diagnostic test · Nonignorable missing data mechanism keyword ·
ROC analysis
1 Introduction
For an ordinal three-category classification problem, the assessment of the per-
formance of a diagnostic test is achieved by the analysis of the receiver operat-
ing characteristic (ROC) surface, which generalizes the ROC curve for binary
diagnostic outcomes. The volume under the ROC surface (VUS) is a summary
index, usually employed for measuring the overall diagnostic accuracy of the
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test. Under correct ordering, values of VUS vary from 1/6, suggesting the test
is no better than chance alone, to 1, which implies a perfect test, i.e. a test
that perfectly discriminates among the three categories. The theoretical con-
struction of the ROC surface and VUS was introduced for the first time by
Scurfield (1996).
In medical studies, the evaluation of the discriminatory ability of a diagnos-
tic test is typically obtained by making inference about its ROC surface and
VUS, based on data from some suitable sample of patients (or units). When
the disease status of each patient can be exactly assessed by means of a gold
standard (GS) test, a set of methods exist to estimate the ROC surface and
VUS of the test in evaluation. See Nakas and Yiannoutsos (2004), Xiong et al
(2006), Li and Zhou (2009) and Kang and Tian (2013), among others. In prac-
tice, however, disease status verification via GS test could be unavailable for
all units in the sample, due to the expensiveness and/or invasiveness of the
GS test. Thus, often, only a subset of patients undergoes disease verification.
In such situations, the implementation of the methods discussed in the above
mentioned papers could only be performed on the verified subjects, typically
yielding biased estimates of ROC surface and VUS. This bias is known as
verification bias.
In order to correct for verification bias, the researchers often assume that
the selection for disease verification does not depend on the disease status,
given the test results and other observed covariates, i.e., they assume that the
true disease status, when missing, is missing at random (MAR, Little and Rubin
(2002)). Under this assumption, there exist few methods to get bias–corrected
inference in ROC surface analysis. Chi and Zhou (2008) proposed a nonpara-
metric likelihood–based approach to obtain bias–corrected estimators for ROC
surface and VUS of an ordinal diagnostic test. In case of continuous diagnostic
tests, To Duc et al (2016) discussed several solutions based on imputation and
re–weighting methods, and proposed four verification bias–corrected estima-
tors of the ROC surface and VUS: full imputation (FI), mean score imputa-
tion (MSI), inverse probability weighting (IPW) and semi–parametric efficient
(SPE) estimators.
However, in some studies the decision to send a subject to verification may
be directly based on the presumed subject’s disease status, or, more generally,
the selection mechanism may depend on some unobserved covariates related
to disease; in these cases, the MAR assumption does not hold and the missing
data mechanism is called nonignorable (NI).
For two-class problems, methods to deal with NI verification bias have
been developed, for instance, in Baker (1995); Zhou and Rodenberg (1998);
Zhou and Castelluccio (2003, 2004); Rotnitzky et al (2006); Fluss et al (2009,
2012); Liu and Zhou (2010). However, the issue of correcting for NI verifica-
tion bias in ROC surface analysis is very scarcely considered in the statistical
literature. This motivated us to develop bias–corrected methods for continu-
ous diagnostic tests with three–class disease status, under a NI missing data
mechanism. In particular, in this paper we adopt parametric regression models
for the disease and the verification processes, extending the selection model of
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Liu and Zhou (2010) to match the case of three–class disease status. Then, we
use likelihood-based estimators of model parameters to derive four estimators
of the VUS. Consistency and asymptotic normality of the proposed estimators
are proved. Estimation of their variance is also discussed.
The rest of the paper is organized as follows. In Section 2, we set the work-
ing model and discuss its identifiability. In Section 3 we present our proposed
bias-corrected VUS estimators, along with theoretical results about consis-
tency and asymptotic normality. The results of a simulation study are pre-
sented in Section 4 and an illustration based on data from the Alzheimer’s
Disease Neuroimaging Initiative is provided in Section 5. Concluding remarks
are left to Section 6. Technical details and a discussion about variance estima-
tion can be found in the appendices.
2 Model for NI missing data mechanism
2.1 Background
Suppose we need to evaluate the predictive ability of a new continuous diag-
nostic test in a context where the disease status of a patient can be described
by three ordered categories, “non–diseased”, “intermediate” and “diseased”,
say. Consider a sample of n subjects and let T , D and A denote the test
result, the disease status and a vector of covariates for each subject, respec-
tively. In this framework, D can be modeled as a trinomial random vector
D = (D1, D2, D3)
⊤, such that Dk is a Bernoulli random variable having mean
θk = Pr(Dk = 1) where θ1 + θ2 + θ3 = 1. Hence, θk represents the probability
that a generic subject, classified according to its disease status, belong to the
class k. We are interested in estimating the VUS of the test T , say µ, which
is defined as (Nakas and Yiannoutsos (2004))
µ = Pr (Ti < Tℓ < Tr|D1i = 1, D2ℓ = 1, D3r = 1)
+
1
2
Pr (Ti < Tℓ = Tr|D1i = 1, D2ℓ = 1, D3r = 1)
+
1
2
Pr (Ti = Tℓ < Tr|D1i = 1, D2ℓ = 1, D3r = 1)
+
1
6
Pr (Ti = Tℓ = Tr|D1i = 1, D2ℓ = 1, D3r = 1)
or, equivalently,
µ =
E (D1iD2ℓD3rIiℓr)
E (D1iD2ℓD3r)
, (1)
where the indices i, ℓ, r refer to three different subjects, Iiℓr = I(Ti < Tℓ <
Tr) + 1/2I(Ti < Tℓ = Tr) + 1/2I(Ti = Tℓ < Tr) + 1/6I(Ti = Tℓ = Tr) and I(·)
is the indicator function.
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When the disease status D is available for all subjects, a natural nonpara-
metric estimator of µ is given by
µˆNP =
n∑
i=1
n∑
ℓ=1,ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
IiℓrD1iD2ℓD3r
n∑
i=1
n∑
ℓ=1,ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
D1iD2ℓD3r
. (2)
However, in many situations not all subjects undergo the verification pro-
cess, and hence, the disease status D is missing in a subset of patients in
the study. Let Vi be the verification status for the i-th subject: Vi = 1 if Di
is observed and Vi = 0 otherwise. We define the observed data as the set
{Oi = (D⊤i , Vi, Ti,A⊤i )⊤, i = 1, . . . , n}. When the true disease status is sub-
ject to NI missingness, estimators working under the MAR assumption cannot
be applied tout court. Our goal is to adjust FI, MSI, IPW and SPE estimators
discussed in To Duc et al (2016) to the framework of NI missingness.
2.2 Model settings
To deal with NI missing data mechanism, in what follows we extend parametric
models adopted in Liu and Zhou (2010) for the two–class problem to the three–
class case. More precisely, with three disease categories, we fix the model for
the verification process as follows
π = Pr(V = 1|D1, D2, T,A) = exp {h(T,A; τπ) + λ1D1 + λ2D2}
1 + exp {h(T,A; τπ) + λ1D1 + λ2D2} , (3)
where D1 and D2 are defined in the previous section, h(T,A; τπ) is, in gen-
eral, an arbitrary working function, and τ π is a set of parameters. Here,
λ = (λ1, λ2)
⊤ is the non-ignorable parameter: the missing data mechanism
is MAR if λ1 = λ2 = 0; NI, otherwise. As for the disease model, we employ
the multinomial logistic regression for the whole sample, i.e.,
ρk = Pr(Dk = 1|T,A) = exp {f(T,A; τ ρk)}
1 + exp {f(T,A; τ ρ1)}+ exp {f(T,A; τ ρ2)}
, (4)
where f(T,A; τ ρk) is an arbitrary working function, and τ ρk is a set of pa-
rameters, for k = 1, 2. The parameters λ, τπ, τ ρ, with τ ρ = (τ
⊤
ρ1
, τ⊤ρ2)
⊤, can
be estimated jointly by using a likelihood–based approach.
It is worth noting that, under (3), an application of Bayes’ rule gives that
Pr(D1 = 1|V = 1, T,A)
Pr(D1 = 1|V = 0, T,A) =
Pr(V = 0|T,A)
Pr(V = 1|T,A) exp {h(T,A; τ π) + λ1} ,
Pr(D2 = 1|V = 1, T,A)
Pr(D2 = 1|V = 0, T,A) =
Pr(V = 0|T,A)
Pr(V = 1|T,A) exp {h(T,A; τ π) + λ2} ,
Pr(D3 = 1|V = 1, T,A)
Pr(D3 = 1|V = 0, T,A) =
Pr(V = 0|T,A)
Pr(V = 1|T,A) exp {h(T,A; τ π)} .
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Therefore,
Pr(D1 = 1|V = 1, T,A)
Pr(D1 = 1|V = 0, T,A)
/
Pr(D3 = 1|V = 1, T,A)
Pr(D3 = 1|V = 0, T,A) = exp(λ1), (5)
Pr(D2 = 1|V = 1, T,A)
Pr(D2 = 1|V = 0, T,A)
/
Pr(D3 = 1|V = 1, T,A)
Pr(D3 = 1|V = 0, T,A) = exp(λ2), (6)
so that, according to (5) and (6), λ1 and λ2 can also be interpreted as log-odds
ratios of belonging to class 1 (instead of class 3) and to class 2 (instead of class
3), respectively, for a verified subject compared to an unverified subject with
the same test result and covariates.
2.3 Parameter estimation
As in Liu and Zhou (2010), in our model, for simplicity, we take h(T,A; τπ) =
τπ1 + τπ2T + A
⊤τ π3 and f(T,A; τ ρk) = τρ1k + τρ2kT +A
⊤τ ρ3k , which is a
natural choice in practice. For fixed T and A, the observed distribution is
fully determined by the three probabilities Pr(D1 = 1, D2 = 0, V = 1|T,A),
Pr(D1 = 0, D2 = 1, V = 1|T,A) and Pr(D1 = 0, D2 = 0, V = 1|T,A). It is
easy to show that
Pr(D1 = 1, D2 = 0, V = 1|T,A)
= Pr(D1 = 1, D2 = 0|T,A)Pr(V = 1|D1 = 1, D2 = 0, T,A)
= Pr(D1 = 1|T,A)Pr(V = 1|D1 = 1, D2 = 0, T,A)
= ρ1π10.
Similarly, we have that
Pr(D1 = 0, D2 = 1, V = 1|T,A) = ρ2π01,
Pr(D1 = 0, D2 = 0, V = 1|T,A) = (1 − ρ1 − ρ2)π00,
with π01 = Pr(V = 1|D1 = 0, D2 = 1, T,A) and π00 = Pr(V = 1|D1 =
0, D2 = 0, T,A). Then,
Pr(V = 1|T,A) = ρ1π10 + ρ2π01 + (1− ρ1 − ρ2)π00,
and Pr(V = 0|T,A) = 1−Pr(V = 1|T,A) = 1−ρ1π10+ρ2π01+(1−ρ1−ρ2)π00.
It follows that the log-likelihood function can be written as
logL(λ, τπ, τ ρ)
=
n∑
i=1
{
D1iVi log(ρ1iπ10i) +D2iVi log(ρ2iπ01i)
+ (1−D1i −D2i)Vi log((1 − ρ1i − ρ2i)π00i)
+ (1− Vi) log(1− ρ1iπ10i − ρ2iπ01i − (1 − ρ1i − ρ2i)π00i)
}
. (7)
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The estimates λˆ, τˆ π, and τˆ ρ can be obtained by maximizing logL(λ, τπ, τ ρ)
or by solving the score equations
0 =
n∑
i=1
{
D1iVi(1 − π10i)− (1− Vi)ρ1iπ10i(1− π10i)
1− ρ1iπ10i − ρ2iπ01i − (1− ρ1i − ρ2i)π00i
}
,
0 =
n∑
i=1
{
D2iVi(1 − π01i)− (1− Vi)ρ2iπ01i(1− π01i)
1− ρ1iπ10i − ρ2iπ01i − (1− ρ1i − ρ2i)π00i
}
,
0 =
n∑
i=1
Ui
{
D1iVi(1− π10i) +D2iVi(1 − π01i) + (1 −D1i −D2i)Vi(1 − π00i)
− (1− Vi)ρ1iπ10i(1 − π10i) + ρ2iπ01i(1 − π01i) + (1 − ρ1i − ρ2i)π00i(1− π00i)
1− ρ1iπ10i − ρ2iπ01i − (1− ρ1i − ρ2i)π00i
}
,
0 =
n∑
i=1
Ui
{
Vi(D1i − ρ1i)− (1− Vi) (π10i − π00i)ρ1i(1− ρ1i)− (π01i − π00i)ρ1iρ2i
1− ρ1iπ10i − ρ2iπ01i − (1 − ρ1i − ρ2i)π00i
}
,
0 =
n∑
i=1
Ui
{
Vi(D2i − ρ2i)− (1− Vi) (π01i − π00i)ρ2i(1− ρ2i)− (π10i − π00i)ρ1iρ2i
1− ρ1iπ10i − ρ2iπ01i − (1 − ρ1i − ρ2i)π00i
}
,
where Ui = (1, Ti,A
⊤
i )
⊤. The above equations are obtained by using the
following results
∂
∂λ1
π10i = π10i(1− π10i),
∂
∂λ2
π01i = π01i(1− π01i),
∂
∂τ⊤π
πd1d2i = Ui(1− πd1d2i)πd1d2i
(here (d1, d2) is a pair in the set {(1, 0), (0, 1), (0, 0)}), and
∂
∂τ⊤ρ1
ρ1i = Uiρ1i(1− ρ1i); ∂
∂τ⊤ρ2
ρ1i = −Uiρ1iρ2i;
∂
∂τ⊤ρ2
ρ2i = Uiρ2i(1− ρ2i); ∂
∂τ⊤ρ1
ρ2i = −Uiρ1iρ2i.
2.4 Identifiability
In this section, we verify that the working model based on (3), with h(T,A; τπ) =
τπ1 + τπ2T +A
⊤τ π3 , and (4), with f(T,A; τ ρk) = τρ1k + τρ2kT +A
⊤τ ρ3k , is
identifiable. Since the log–likelihood (7) is fully determined by the three prob-
abilities Pr(D1 = 1, D2 = 0, V = 1|T,A), Pr(D1 = 0, D2 = 1, V = 1|T,A)
and Pr(D1 = 0, D2 = 0, V = 1|T,A), we have to show that such probabilities
are uniquely determined by the parameters for all possible T and A. For the
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sake of simplicity, in the remainder of this section the auxiliary covariate A is
omitted (actually, we can always view A as fixed while varying T ).
Let ξ = (λ1, λ2, τπ1 , τπ2 , τρ11 , τρ21 , τρ12 , τρ22)
⊤ be the set of parameters. For
given T = t, we can write
log(ρ1π10) = (τρ11 + τρ21t)− log {1 + exp(τρ11 + τρ21t) + exp(τρ12 + τρ22t)}
+ (τπ1 + τπ2t) + λ1 − log {1 + exp(τπ1 + τπ2t) exp(λ1)} ,
log(ρ2π01) = (τρ12 + τρ22t)− log {1 + exp(τρ11 + τρ21t) + exp(τρ12 + τρ22t)}
+ (τπ1 + τπ2t) + λ2 − log {1 + exp(τπ1 + τπ2t) exp(λ2)} ,
log(ρ3π00) = − log {1 + exp(τρ11 + τρ21 t) + exp(τρ12 + τρ22t)} + (τπ1 + τπ2t)
− log {1 + exp(τπ1 + τπ2t)} .
Let x(t) = τπ1 + τπ2t, y(t) = τρ11 + τρ21 t and z(t) = τρ12 + τρ22t, for each
t ∈ R. The above expressions, which refer to the quantities characterizing the
log–likelihood function (7), can be rewritten as
log(ρ3π00) = − log {1 + exp(y(t)) + exp(z(t))}+ x(t) − log {1 + exp(x(t))} ,
log(ρ1π10) = y(t)− log {1 + exp(y(t)) + exp(z(t))} + x(t) + λ1
− log {1 + exp(x(t)) exp(λ1)}
= log(ρ3π00) + log {1 + exp(x(t))} + y(t) + λ1
− log {1 + exp(x(t)) exp(λ1)}
= log(ρ3π00) + y(t) + log {1 + exp(x(t))} − log {exp(−λ1) + exp(x(t))}
= log(ρ3π00) + y(t) + log
{
1 + exp(x(t))
exp(−λ1) + exp(x(t))
}
,
log(ρ2π01) = z(t)− log {1 + exp(y(t)) + exp(z(t))}+ x(t) + λ2
− log {1 + exp(x(t)) exp(λ2)}
= log(ρ3π00) + z(t) + log
{
1 + exp(x(t))
exp(−λ2) + exp(x(t))
}
.
Now, assume that there are two distinct points ξ and ξ∗ (ξ 6= ξ∗) in the
parameter space, such that the following equations (with obvious notation)
hold:
ρ1π10 = ρ
∗
1π
∗
10, (8)
ρ2π01 = ρ
∗
2π
∗
01, (9)
ρ3π00 = ρ
∗
3π
∗
00, (10)
for all t ∈ R. By using (10), the equations (8) and (9) are equivalent to
y(t)− y∗(t)
= log
{
1 + exp(x∗(t))
exp(−λ∗1) + exp(x∗(t))
}
− log
{
1 + exp(x(t))
exp(−λ1) + exp(x(t))
}
, (11)
z(t)− z∗(t)
= log
{
1 + exp(x∗(t))
exp(−λ∗2) + exp(x∗(t))
}
− log
{
1 + exp(x(t))
exp(−λ2) + exp(x(t))
}
, (12)
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respectively. In (11) and (12) the left hand sides are straight lines. Thus, in
order to (11) and (12) hold for all t, the right hand sides must be constants. If
these constants were 0 (because λ1 = λ
∗
1 = λ2 = λ
∗
2 = 0), then (10) would no
longer hold for ξ 6= ξ∗ and all t. Alternatively, the right hand sides of (11) and
(12) are non-zero constants if τπ2 = τ
∗
π2
= 0. Then, as a consequence, (10) still
is valid, for ξ 6= ξ∗ and all t, eventually if τρ21 = τ∗ρ21 = 0 and τρ22 = τ∗ρ22 = 0.
This allows us to state that: if Pr(Dk|T ) 6= Pr(Dk), with k = 1, 2, then the
considered model (with the particular choice for the functions h and f) is
identifiable, i.e., the joint probabilities Pr(D1 = 1, D2 = 0, V = 1|T = t),
Pr(D1 = 0, D2 = 1, V = 1|T = t) and Pr(D1 = 0, D2 = 0, V = 1|T = t) are
determined by a unique set of parameters. Of course, this claim can be easily
extended to handle the presence of a covariate vector, A.
3 The proposal
3.1 VUS estimators
Let ρk(v) = Pr(Dk = 1|V = v, T,A), for k = 1, 2 and v = 0, 1. It is easy to
see, for instance, that
ρ1(v) =
Pr(V = v,D1 = 1|D2 = 0, T,A)
Pr(V = v|T,A)
=
Pr(V = v|D1 = 1, D2 = 0, T,A)Pr(D1 = 1|T,A)
Pr(V = v|T,A) .
Hence, we can get, in particular,
ρ1(0) =
(1− π10)ρ1
(1− π10)ρ1 + (1− π01)ρ2 + (1− π00)ρ3 ,
ρ2(0) =
(1− π01)ρ2
(1− π10)ρ1 + (1− π01)ρ2 + (1− π00)ρ3 ,
ρ3(0) =
(1− π00)ρ3
(1− π10)ρ1 + (1− π01)ρ2 + (1− π00)ρ3 .
Clearly, we also may consider quantities as
ρ1(1) =
π10ρ1
π10ρ1 + π01ρ2 + π00ρ3
.
Then, we observe that
E(D1iD2ℓD3rIiℓr) = ET,A {IiℓrE(D1iD2ℓD3r|Ti,Ai, Tℓ,Aℓ, Tr,Ar)} ,
= ET,A {IiℓrE(D1i|Ti,Ai)E(D2ℓ|Tℓ,Aℓ)E(D3r|Tr,Ar)} ,
= ET,A (ρ1iρ2ℓρ3rIiℓr) .
Similarly, we have
E(D1iD2ℓD3r) = ET,A (ρ1iρ2ℓρ3r) ,
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so that (1) can be rewritten as
µ =
ET,A (ρ1iρ2ℓρ3rIiℓr)
ET,A (ρ1iρ2ℓρ3r)
. (13)
Equation (13) suggests how to build estimators of VUS when some disease
labels are missing in the sample: we can use suitable estimates ρˆki to replace
the Dki’s in (2). Therefore, a FI estimator of VUS is simply
µˆFI =
n∑
i=1
n∑
ℓ=1,ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
Iiℓrρˆ1iρˆ2ℓρˆ3r
n∑
i=1
n∑
ℓ=1,ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
ρˆ1iρˆ2ℓρˆ3r
, (14)
where ρˆki (k = 1, 2, 3 and i = 1, . . . , n) are the estimated disease probabilities
obtained from the disease model (4).
Since E[Viρk(1)i + (1 − Vi)ρk(0)i|T,A] = ρki, an alternative FI estima-
tor of VUS could be obtained by replacing Dki’s in (2) with the estimates
D˜ki,FI = Viρˆk(1)i + (1 − Vi)ρˆk(0)i. Unlike FI approach, MSI estimator only
replace the disease status Dki by the estimate ρˆk(0)i for unverified subjects.
Define Dki,MSI = ViDki+(1−Vi)ρk(0)i and let D˜ki,MSI be the estimated version
with ρk(0)i replaced by ρˆk(0)i, and
ρˆ1(0)i =
(1− πˆ10i)ρˆ1i
(1 − πˆ10i)ρˆki + (1− πˆ01i)ρˆ2i + (1− πˆ00i)ρˆ3i ,
ρˆ2(0)i =
(1− πˆ01i)ρˆ2i
(1 − πˆ10i)ρˆ1i + (1− πˆ01i)ρˆ2i + (1− πˆ00i)ρˆ3i ,
ρˆ3(0)i =
(1− πˆ00i)ρˆ3i
(1 − πˆ10i)ρˆ1i + (1− πˆ01i)ρˆ2i + (1− πˆ00i)ρˆ3i .
Here, πˆ10i = P̂r(Vi = 1|D1i = 1, D2i = 0, Ti, Ai), πˆ01i = P̂r(Vi = 1|D1i =
0, D2i = 1, Ti, Ai) and πˆ00i = P̂r(Vi = 1|D1i = 0, D2i = 0, Ti, Ai). Such
estimates are derived from the verification model (3). Then, the MSI estimator
of VUS is
µˆMSI =
n∑
i=1
n∑
ℓ=1,ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
IiℓrD˜1i,MSID˜2ℓ,MSID˜3r,MSI
n∑
i=1
n∑
ℓ=1,ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
D˜1i,MSID˜2ℓ,MSID˜3r,MSI
. (15)
In the IPW approach, instead, each observation in the subset of verified
units is weighted by the inverse of the probability that the unit was selected
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for verification. Thus, the IPW estimator of VUS is
µˆIPW =
n∑
i=1
n∑
ℓ=1,ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
IiℓrViVℓVrD1iD2ℓD3rπˆ
−1
i πˆ
−1
ℓ πˆ
−1
r
n∑
i=1
n∑
ℓ=1,ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
ViVℓVrD1iD2ℓD3rπˆ
−1
i πˆ
−1
ℓ πˆ
−1
r
. (16)
Clearly, the estimates πˆi also arise from the selection model (3).
The last estimator is the pseudo doubly robust (PDR) estimator. We define
Dki,PDR =
ViDki
πi
− ρk(0)i(Vi − πi)
πi
.
An estimated version, D˜ki,PDR, is obtained by entering the estimates πˆi and
ρˆk(0)i in the expression above. Then, the PDR estimator of VUS is
µˆPDR =
n∑
i=1
n∑
ℓ=1,ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
IiℓrD˜1i,PDRD˜2ℓ,PDRD˜3r,PDR
n∑
i=1
n∑
ℓ=1,ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
D˜1i,PDRD˜2ℓ,PDRD˜3r,PDR
. (17)
The PDR estimator has the same nature as the SPE estimator discussed in
To Duc et al (2016) under MAR assumption. However, under NI missing data
mechanism it no longer has the doubly robust property. In fact, correct spec-
ification of both the verification model and the disease model is required for
the PDR estimator to be consistent.
Note that all VUS estimators basically require maximum likelihood esti-
mates of the parameters λ, τ π and τ ρ of the working models (3) and (4).
3.2 Asymptotic behavior
Let ξ = (λ⊤, τ⊤π , τ
⊤
ρ )
⊤ be the nuisance parameter. Observe that the proposed
VUS estimators can be found as solutions of appropriate estimating equations
(solved along with the score equations). The estimating functions for FI, MSI,
IPW and PDR estimators have generic term (corresponding to a generic triplet
of sample units), respectively,
Giℓr,FI(µ, ξ) = ρ1i(τ ρ)ρ2ℓ(τ ρ)ρ3r(τ ρ) (Iiℓr − µ) ,
Giℓr,MSI(µ, ξ) = D1i,MSI(ξ)D2ℓ,MSI(ξ)D3r,MSI(ξ) (Iiℓr − µ) ,
Giℓr,IPW(µ, ξ) =
ViVℓVrD1iD2ℓD3r
πi(ξ)πℓ(ξ)πk(ξ)
(Iiℓr − µ) ,
Giℓr,PDR(µ, ξ) = D1i,PDR(ξ)D2ℓ,PDR(ξ)D3r,PDR(ξ) (Iiℓr − µ) .
In the following, we will use the general notation Giℓr,∗(µ, ξ), where the star
stands for FI, MSI, IPW and PDR.
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Recall that the nuisance parameter ξ is estimated by maximizing the log–
likelihood function (7). Let Si(ξ) be the i–th subject’s contribution to the
score function, I(ξ) = −E
(
∂
∂ξ⊤
Si(ξ)
)
the Fisher information matrix for ξ
and ξˆ the maximum likelihood estimator. Let µ0 be the true VUS value, and
ξ0 = (λ
⊤
0 , τ
⊤
0π, τ
⊤
0ρ)
⊤ the true value of ξ. To give general theoretical results,
we assume that:
(C1) the U–process
Un,∗(µ, ξ) =
√
n {G∗(µ, ξ)− e∗(µ, ξ)}
is stochastically equicontinuous, where
G∗(µ, ξ) =
1
6n(n− 1)(n− 2)
n∑
i=1
n∑
ℓ=1,ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
{
Giℓr,∗(µ, ξ) +Girℓ,∗(µ, ξ)
+Gℓir,∗(µ, ξ) +Gℓri,∗(µ, ξ) +Griℓ,∗(µ, ξ) +Grℓi,∗(µ, ξ)
}
and
e∗(µ, ξ) =
1
6
E
{
Giℓr,∗(µ, ξ) +Girℓ,∗(µ, ξ) +Gℓir,∗(µ, ξ) +Gℓri,∗(µ, ξ)
+Griℓ,∗(µ, ξ) +Grℓi,∗(µ, ξ)
}
;
(C2) e∗(µ, ξ) is differentiable in (µ, ξ), and
∂e∗(µ, ξ0)
∂µ
∣∣∣∣∣
µ=µ0
6= 0;
(C3) G∗(µ, ξ) and
∂G∗(µ, ξ)
∂ξ⊤
converges uniformly (in probability) to e∗(µ, ξ)
and
∂e∗(µ, ξ)
∂ξ⊤
, respectively.
We now state the two main results about consistency and asymptotic normality
of the proposed estimators, whose proves are given in Appendix 1.
Theorem 1 (Consistency) Suppose that conditions (C1)–(C3) hold. Then,
under the verification model (3) and the disease model (4), µˆ∗
p→ µ0.
Recall that here the star indicates FI, MSI, IPW, and PDR.
Theorem 2 (Asymptotic normality) Under conditions (C1)–(C3), if the
verification model (3) and the disease model (4) hold, then
√
n (µˆ∗ − µ0) d→ N (0, Λ∗),
where Λ∗ is given in (20).
It is worth noting that conditions (C1)–(C3) hold in our working model,
which is based on (3), with h(T,A; τπ) = τπ1 + τπ2T +A
⊤τπ3 , and (4), with
f(T,A; τ ρk) = τρ1k+τρ2kT +A
⊤τ ρ3k . In Appendix 1 we discuss how to obtain
a consistent estimator of Λ∗.
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4 Simulation study
In this section, we provide empirical evidence, through simulation experiments,
on the behavior of the proposed VUS estimators in finite samples. The number
of replications in each simulation experiment is set to be 1000.
In the study, we consider two scenarios which correspond to quite different
values of the true VUS. For both scenarios, we fix three sample sizes: 250, 500
and 1500.
In the first scenario, for each unit, we generate the test result Ti and a
covariate Ai from a bivariate normal distribution,
(Ti, Ai) ∼ N2
((
3.7
1.85
)
,
(
3.71 1.36
1.36 3.13
))
.
The disease status Di is generated according to model (4) with f(T,A; τ ρ1) =
4.6− 3.3T − 6.4A and f(T,A; τρ2) = 4 − 1.7T − 3.2A. Then, the verification
label Vi is obtained according to model (3) with h(T,A; τπ) = 1+1.2T −1.5A
and λ1 = −2.5, λ2 = −1. Under such data generating process, θ1 = 0.4,
θ2 = 0.35, θ3 = 0.25, and the verification rate is roughly 0.57. The true VUS
value is 0.791. In the second scenario, we generate the test result and the
covariate from independent normal distributions. Specifically, Ti ∼ N (0.65, 1)
and Ai ∼ N (−0.3, 0.64). The disease statusDi is generated according to model
(4) with f(T,A; τ ρ1) = 4.6− 3.3T − 6.4A and f(T,A; τ ρ2) = 4− 1.7T − 3.2A.
Then, Vi is obtained according to model (3) with h(T,A; τπ) = 1+1.2T−1.5A
and λ1 = −2.5, λ2 = −1. Under this setting, θ1 = 0.55, θ2 = 0.32, θ3 = 0.13,
and the verification rate is roughly 0.58. The true VUS value is 0.387.
Table 1 contains Monte Carlo means, Monte Carlo standard deviations
and estimated standard deviations for the proposed VUS estimators (FI, MSI,
IPW, PDR) in the two considered scenarios, at the chosen sample sizes. The ta-
ble also reports the empirical coverages of the 95% confidence intervals for the
VUS, obtained through the normal approximation approach applied to each
estimator. To make a comparison, Table 1 also gives the results for the semi-
parametric efficient estimator (SPE) discussed in To Duc et al (2016), whose
realizations are obtained, in all experiments, under the MAR assumption, i.e.,
by setting λ1 = λ2 = 0 in model (3). The comparison allows us to evaluate the
possible impact of an incorrect hypothesis MAR on the most robust estimator
among those, FI, MSI, IPW and SPE, which are built to work under ignorable
missing data mechanism (see To Duc et al (2016)).
Overall, simulation results are consistent with our theoretical findings and
show the usefulness of the proposed estimators, which also arises from the
comparison with the SPE estimator used improperly. The results also show a
good behavior of the estimated standard deviations, which are generally close
to the corresponding Monte Carlo values. In general, FI and MSI estimators
seem to be more efficient than IPW and PDR estimators. However, for all es-
timators, acceptable bias levels and sufficiently accurate associated confidence
intervals seem to require a large sample size (at least 500, and, prudently, even
higher).
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Table 1 Monte Carlo means (MCmean), relative bias (Bias), Monte Carlo standard devi-
ations (MCds) and estimated standard deviations (Esd) for the proposed VUS estimators,
and the SPE estimator under MAR assumption. CP denotes Monte Carlo coverages for the
95% confidence intervals, obtained through the normal approximation approach applied to
each estimator.
Sample size Estimators MCmean Bias(%) MCsd Esd CP(%)
Scenario I:
VUS = 0.791
n = 250
FI 0.772 -2.4 0.056 0.050 89.9
MSI 0.770 -2.7 0.057 0.051 90.6
IPW 0.770 -2.6 0.070 0.061 88.1
PDR 0.766 -3.2 0.085 0.075 90.8
SPE (MAR) 0.771 -2.5 0.073 0.138 93.2
n = 500
FI 0.783 -1.0 0.035 0.032 93.3
MSI 0.782 -1.1 0.036 0.033 93.4
IPW 0.782 -1.2 0.047 0.042 92.2
PDR 0.782 -1.2 0.053 0.058 94.0
SPE (MAR) 0.771 -2.6 0.047 0.040 93.0
n = 1500
FI 0.790 -0.2 0.016 0.016 95.0
MSI 0.789 -0.2 0.016 0.016 95.2
IPW 0.788 -0.3 0.025 0.024 94.4
PDR 0.789 -0.3 0.025 0.024 95.2
SPE (MAR) 0.771 -2.5 0.027 0.025 89.4
Scenario II:
VUS = 0.387
n = 250
FI 0.368 -5.0 0.064 0.057 87.4
MSI 0.367 -5.2 0.065 0.059 87.9
IPW 0.377 -2.6 0.084 0.074 87.6
PDR 0.369 -4.6 0.086 0.075 89.5
SPE (MAR) 0.346 -10.6 0.063 0.058 84.5
n = 500
FI 0.379 -2.0 0.045 0.041 90.9
MSI 0.379 -2.1 0.046 0.042 91.3
IPW 0.380 -1.8 0.060 0.056 91.2
PDR 0.381 -1.6 0.060 0.053 92.0
SPE (MAR) 0.345 -10.8 0.044 0.042 76.5
n = 1500
FI 0.388 0.2 0.023 0.022 94.2
MSI 0.388 0.2 0.023 0.023 94.3
IPW 0.388 0.3 0.034 0.032 94.9
PDR 0.389 0.4 0.033 0.029 93.2
SPE (MAR) 0.346 -10.7 0.026 0.025 76.5
This issue of poor accuracy has already been noted by several authors,
including Liu and Zhou (2010), in the context of two-class classification prob-
lems. In our experience, the trouble appears to arise because of a bad behavior
of the maximum likelihood estimates in the verification and disease models.
If the sample size is not large enough, the data do not contain enough infor-
mation to effectively estimate the parameters λ, τπ, τ ρ1 and τ ρ2 . It seems
particularly difficult to get good estimates of nonignorable parameters.
Table 2, giving the Monte Carlo means for the maximum likelihood esti-
mators of the elements of λ, τ π, τ ρ1 and τ ρ2 , for the three considered sample
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sizes, allows us to look at the bias of the estimators. More importantly, Fig-
ure 1 and Figure 2 (which refer to scenario I and II, respectively) graphically
depict values of the estimates of λ1, λ2 and τπ1 obtained in the thousand repli-
cations, for each sample size. The plots clearly show the great variability of the
maximum likelihood estimates at lower sample sizes, with many values dra-
matically different from the corresponding target values. With larger sample
size, this phenomenon almost completely vanishes, the maximum likelihood
estimators behave pretty well, with a positive impact on the behavior of the
VUS estimators.
Table 2 Monte Carlo means (MCmean) for the maximum likelihood estimators of the
elements of nuisance parameters λ, τπ, τρ1 and τρ2 .
Scenario I Scenario II
True MCmean True MCmean
n = 250 n = 500 n = 1500 n = 250 n = 500 n = 1500
λ1 -2.00 -1.01 -1.76 -1.95 -2.50 -2.09 -2.30 -2.50
λ2 -1.00 -0.45 -0.87 -0.98 -1.00 -0.99 -0.96 -0.97
τπ1 2.00 1.25 1.80 1.95 1.00 1.17 1.00 1.00
τπ2 0.50 0.65 0.55 0.51 1.20 1.39 1.28 1.22
τπ3 -1.20 -1.24 -1.22 -1.21 -1.50 -1.25 -1.40 -1.51
τρ11 15.00 15.53 15.28 15.10 4.60 4.44 4.58 4.66
τρ21 -3.30 -3.41 -3.36 -3.32 -3.30 -3.29 -3.33 -3.34
τρ31 -0.70 -0.89 -0.78 -0.72 -6.40 -6.94 -6.70 -6.48
τρ12 9.50 10.03 9.71 9.57 4.00 4.12 4.11 4.05
τρ22 -1.70 -1.79 -1.73 -1.71 -1.70 -1.77 -1.76 -1.73
τρ32 -0.30 -0.40 -0.34 -0.31 -3.20 -3.62 -3.42 -3.25
5 An illustration
To illustrate the application of our proposed methods, we used data from
Alzheimer’s Disease Neuroimaging Initiative (ADNI, adni.loni.usc.edu). ADNI
was launched in 2003 as a public-private partnership with the primary goal of
finding suitable diagnostic tests or biomarkers for early detection and tracking
of the Alzheimer’s disease (see www.adni-info.org for up-to-date information).
Study subjects are classified in one of three classes, i.e., cognitively normal
(CN), mild cognitive impairment (MCI), and Alzheimer’s disease (AD) on
the basis of neuropsychological tests. Various clinical, imaging, genetic and
biochemical markers are also available. Among them, we consider cerebrospinal
fluid (CSF) tau protein as the primary marker, and amyloid beta 1-42 (Aβ1-
42) as a covariate. The full dataset in our illustration refers to 1209 subjects
(CN: 363, MCI: 618, AD: 228 at baseline visit). Exploratory analysis suggests
that high values of CFS tau protein are associated with severe disease status.
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Fig. 1 Values of the estimates of λ1, λ2, and τπ1 , obtained in thousand Monte Carlo repli-
cations (Scenario I), for each sample size. The horizontal lines indicate the true parameter
values.
Here, we want to evaluate the accuracy of CSF tau protein as a marker for
the Alzheimer’s disease assuming nonignorable missingness in the disease sta-
tus of some patients. To this aim, we induce missingness by randomly selecting
patients from the three classes in different proportions. Then, about 66% and
16% patients in AD and MCI classes, respectively, are given a missing dis-
ease status. No missing status is set in the CN class. Overall, in the resulting
dataset, for 76.4% of the subjects the true disease status is present. For con-
venience, values of the considered variables, i.e., CSF tau protein and amyloid
beta 1-42, are standardized. In what follows, the standardized variables will
be denoted as T and A, respectively.
We focus on VUS estimation of marker T by applying the FI, MSI, IPW
and PDR estimators proposed in Section 3. For the sake of comparison, bias–
corrected VUS estimators under MAR assumption (To Duc et al (2016)), are
also employed. Estimates under the MAR assumption are obtained through
the R package bcROCsurface (To Duc (2017)), in which the verification model
is fitted by using logistic regression with T and A as covariates, and the disease
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Fig. 2 Values of the estimates of λ1, λ2, and τπ1 , obtained in thousand Monte Carlo repli-
cations (Scenario II), for each sample size. The horizontal lines indicate the true parameter
values.
model is fitted by means of multinomial logistic regression with T and A as
regressors. Moreover, we also compute the VUS estimate based on the full
dataset (Full estimate).
The maximum likelihood estimate of the non-ignorable parameter λ =
(λ1, λ2)
⊤ in the verification model (3) is (18.766, 3.344)⊤. The log-likelihood
ratio test for the hypothesis H0 : λ = 0 versus HA : λ 6= 0 achieves a p-value
of 0.0066, indicating that the non-ignorable effect is significant.
Table 3 shows the Full and the bias-corrected NI and MAR estimates of
VUS. The table also gives the estimated standard deviations, and approxi-
mated 95% confidence intervals. For the Full estimate, the bootstrap standard
deviation is reported (250 bootstrap replications). Standard deviations of NI
and MAR estimates are obtained by using asymptotic theory. As expected,
taking the Full estimate as a benchmark, MAR estimators seem to overesti-
mate the VUS, whereas the NI estimators appear to perform better, in par-
ticular FI and MSI. Consistently with simulation results in Table 1, the NI
bias-corrected FI and MSI estimators appear also to be more efficient than
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Table 3 ADNI dataset. Estimates of VUS for the standardized CSF tau protein,
associated estimated standard deviations (SD) and 95% confidence intervals. SD
for Full estimated is obtained via bootstrap resampling.
VUS Estimate SD 95% confidence interval
Full 0.338 0.019 (0.301, 0.375)
NI
FI 0.335 0.016 (0.303, 0.368)
MSI 0.333 0.018 (0.298, 0.368)
IPW 0.352 0.024 (0.305, 0.398)
PDR 0.344 0.021 (0.302, 0.384)
MAR
FI 0.369 0.031 (0.309, 0.429)
MSI 0.366 0.031 (0.304, 0.427)
IPW 0.373 0.034 (0.307, 0.440)
SPE 0.362 0.033 (0.297, 0.426)
the IPW and PDR estimators. Taking into account that the logistic model (3)
used for the verification process does not reflect the induced verification mech-
anism, this seems to suggest that the NI bias-corrected FI and MSI estimators
are less sensitive to possible misspecifications of the verification process.
6 Conclusion
In this paper, we have proposed four bias–corrected estimators of VUS under
NI missing data mechanism. The estimators are obtained by a likelihood–
based approach, which uses the verification model (3) together with the dis-
ease model (4). The identifiability of the joint model is proved, and hence, the
nuisance parameters can be estimated by maximizing the log–likelihood func-
tion or solving the score equations. Consistency and asymptotic normality of
the proposed FI, MSI, IPW and PDR estimators are established, and variance
estimation is discussed.
The proposed VUS estimators are pretty easy to implement and require
the use of some numerical routine to maximize the log–likelihood function (or
to solve the score equations). Our simulation results show their usefulness,
whilst confirming the evidence emerging in the two–class case, according to
which a reasonable large sample size is necessary to make sufficiently accurate
inference. In practice, among FI, MSI, IPW and PDR estimators, we would
reccommend FI and MSI estimators thanks to their greater efficiency.
The poor accuracy problem seems to be related to an intrinsic difficulty of
the maximum likelihood method in providing accurate estimates of the param-
eters of the disease and verification models, in particular of the nonignorable
parameters. Overcoming this drawback is a stimulating challenge and deserves
further investigation.
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Appendix 1
Proves
Proof of Theorem 1. We can show that E{Giℓr,∗(µ0, ξ0)} = 0 (see the Appendix 2). Then
e∗(µ0, ξ0) = 0, and, by condition (C2) and an application of implicit function theorem,
there exists a neighborhood of ξ0 in which a continuously differentiable function, m(ξ), is
uniquely defined such that m(ξ0) = µ0 and e∗(m(ξ), ξ) = 0. Since the maximum likelihood
estimator ξˆ is consistent, i.e., ξˆ
p→ ξ0, we have that µ˜∗ = m(ξˆ) p→ µ0. On the other hand,
G∗(µˆ∗, ξˆ) = 0 and condition (C3) implies that e∗(µˆ∗, ξˆ)
p→ 0. Thus, µˆ∗ p→ µ˜∗. ⊓⊔
Proof of Theorem 2. We have
0 =
√
nG∗(µˆ∗, ξˆ)
0 =
√
nG∗(µˆ∗, ξˆ) +
√
ne∗(µˆ∗, ξˆ)−
√
ne∗(µˆ∗, ξˆ).
Since e∗(µ0, ξ0) = 0, we get
0 =
√
nG∗(µˆ∗, ξˆ) +
√
ne∗(µˆ∗, ξˆ)−
√
ne∗(µˆ∗, ξˆ) +
√
ne∗(µ0, ξ0)−
√
ne∗(µ0, ξ0)
=
√
n
{
G∗(µˆ∗, ξˆ) − e∗(µˆ∗, ξˆ)
}
+
√
n
{
e∗(µˆ∗, ξˆ)− e∗(µ0, ξ0)
}
+
√
ne∗(µ0, ξ0)
−√nG∗(µ0, ξ0) +
√
nG∗(µ0, ξ0)
=
[√
n
{
G∗(µˆ∗, ξˆ)− e∗(µˆ∗, ξˆ)
}
−√n {G∗(µ0, ξ0)− e∗(µ0, ξ0)}
]
+
√
n
{
e∗(µˆ∗, ξˆ)− e∗(µ0, ξ0)
}
+
√
nG∗(µ0, ξ0).
Condition (C1) implies that the first term in right hand side of the last identity is op(1).
Using the Taylor expansion, we have
0 = op(1) +
√
n
{
e∗(µˆ∗, ξˆ)− e∗(µ0, ξ0)
}
+
√
nG∗(µ0, ξ0)
= op(1) +
√
n(µˆ∗ − µ0)∂e∗(µ, ξ0)
∂µ
∣∣∣∣∣
µ=µ0
+
√
n(ξˆ − ξ0)∂e∗(µ0, ξ)
∂ξ⊤
∣∣∣∣∣
ξ=ξ0
+
√
nG∗(µ0, ξ0). (18)
It is straightforward to show that
∂e∗(µ, ξ0)
∂µ
∣∣∣∣∣
µ=µ0
= −Pr(D1 = 1)Pr(D2 = 1)Pr(D3 = 1) = −θ1θ2θ3.
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By standard results on the limit distribution of U-statistics (van der Vaart 2000, Theorem
12.3, Chap. 12),
√
nUn,∗(µ0, ξ0) =
√
n {G∗(µ0, ξ0)− e∗(µ0, ξ0)} =
√
nG∗(µ0, ξ0)
p→ √nG˜∗(µ0, ξ0),
where
√
nG˜∗(µ, ξ) is the projection of Un,∗ onto the set of all statistics of the form
√
nG˜n,∗(µ, ξ) =
1
2
√
n
n∑
i=1
E
{
Giℓr,∗(µ, ξ) +Girℓ,∗(µ, ξ) +Gℓir,∗(µ, ξ)
+Gℓri,∗(µ, ξ) +Griℓ,∗(µ, ξ) +Grℓi,∗(µ, ξ)
∣∣Oi
}
for ℓ 6= i and r 6= ℓ, r 6= i. For the maximum likelihood estimator ξˆ, we can write
√
n
(
ξˆ − ξ0
)
=
1√
n

−∂E {Si(ξ)}
∂ξ⊤
∣∣∣∣∣
ξ=ξ0


−1
n∑
i=1
Si(ξ0) + op(1)
=
1√
n
I(ξ)−1
n∑
i=1
Si(ξ0) + op(1).
Hence, from (18),
θ1θ2θ3
√
n(µˆ∗ − µ0)
= op(1) +
1√
n
∂e∗(µ0, ξ)
∂ξ⊤
∣∣∣∣∣
ξ=ξ0
I(ξ)−1
n∑
i=1
Si(ξ0)
+
1
2
√
n
n∑
i=1
E
{
Giℓr,∗(µ0, ξ0) +Girℓ,∗(µ0, ξ0) +Gℓir,∗(µ0, ξ0)
+Gℓri,∗(µ0, ξ0) +Griℓ,∗(µ0, ξ0) +Grℓi,∗(µ0, ξ0)
∣∣Oi
}
= op(1) +
1√
n
n∑
i=1
[
∂e∗(µ0, ξ)
∂ξ⊤
∣∣∣∣∣
ξ=ξ0
I(ξ)−1Si(ξ0)
+
1
2
E
{
Giℓr,∗(µ0, ξ0) +Girℓ,∗(µ0, ξ0) +Gℓir,∗(µ0, ξ0)
+Gℓri,∗(µ0, ξ0) +Griℓ,∗(µ0, ξ0) +Grℓi,∗(µ0, ξ0)
∣∣Oi
}]
(19)
= op(1) +
1√
n
n∑
i=1
Qi,∗(µ0, ξ0) = op(1) +
1√
n
Q∗(µ0, ξ0).
Note that the observed data Oi are i.i.d, then Qi,∗(µ0, ξ0) are also i.i.d. In addition, we
easily show that
0 = E
[
E
{
Giℓr,∗(µ0, ξ0) +Girℓ,∗(µ0, ξ0) +Gℓir,∗(µ0, ξ0) +Gℓri,∗(µ0, ξ0)
+Griℓ,∗(µ0, ξ0) +Grℓi,∗(µ0, ξ0)
∣∣Oi
}]
.
Therefore, E{Qi,∗(µ0, ξ0)} = 0, and 1√nQ∗(µ0, ξ0)
d→ N (0,Var {Qi,∗(µ0, ξ0)}) by the Cen-
tral Limit Theorem. It follows that
√
n (µˆ∗ − µ0) d→ N (0, Λ∗) ,
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where
Λ∗ =
Var {Qi,∗(µ0, ξ0)}
θ21θ
2
2θ
2
3
. (20)
⊓⊔
Variance estimation
Under condition (C3), a consistent estimator of Λ∗ can be obtained as
Λˆ∗ =
Var
{
Qˆi,∗(µˆ∗, ξˆ)
}
θˆ21,∗θˆ
2
2,∗ θˆ
2
3,∗
=
1
n−1
n∑
i=1
Qˆ2i,∗(µˆ∗, ξˆ)
θˆ21,∗θˆ
2
2,∗ θˆ
2
3,∗
, (21)
where θˆk,∗ are the estimates of the disease probabilities, θk for k = 1, 2, 3. Specifically,
θˆk,FI =
1
n
n∑
i=1
ρˆki, θˆk,MSI =
1
n
n∑
i=1
D˜ki,MSI, θˆk,IPW =
n∑
i=1
ViDkiπˆ
−1
i /
n∑
i=1
Viπˆ
−1
i and θˆk,PDR =
1
n
n∑
i=1
D˜ki,PDR.
According to (19), we have that
Qˆi,∗(µˆ∗, ξˆ)
=


1
(n− 1)(n− 2)
n∑
i=1
n∑
ℓ=i
ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
∂Giℓr,∗(µˆ∗, ξ)
∂ξ⊤
∣∣∣∣
ξ=ξˆ


×
{
−
n∑
i=1
∂Si(ξ)
∂ξ⊤
∣∣∣∣
ξ=ξˆ
}−1
Si(ξˆ)
+
1
2(n− 1)(n− 2)
n∑
ℓ=1
ℓ 6=i
n∑
r=1
r 6=i,r 6=ℓ
{
Giℓr,∗(µˆ∗, ξˆ) +Girℓ,∗(µˆ∗, ξˆ) +Gℓir,∗(µˆ∗, ξˆ)
+Gℓri,∗(µˆ∗, ξˆ) +Griℓ,∗(µˆ∗, ξˆ) +Grℓi,∗(µˆ∗, ξˆ)
}
.
In addition, for fixed i, we also have that
n∑
ℓ=1
ℓ 6=i
n∑
r=1
r 6=i,r 6=ℓ
{
Giℓr,∗(µˆ∗, ξˆ) +Gikr,∗(µˆ∗, ξˆ)
}
= 2
n∑
ℓ=1
ℓ 6=i
n∑
r=1
r 6=i,r 6=ℓ
Giℓr,∗(µˆ∗, ξˆ),
n∑
ℓ=1
ℓ 6=i
n∑
r=1
r 6=i,r 6=ℓ
{
Gℓir,∗(µˆ∗, ξˆ) +Griℓ,∗(µˆ∗, ξˆ)
}
= 2
n∑
ℓ=1
ℓ 6=i
n∑
r=1
r 6=i,r 6=ℓ
Gℓir,∗(µˆ∗, ξˆ),
n∑
ℓ=1
ℓ 6=i
n∑
r=1
r 6=i,r 6=ℓ
{
Gℓri,∗(µˆ∗, ξˆ) +Grℓi,∗(µˆ∗, ξˆ)
}
= 2
n∑
ℓ=1
ℓ 6=i
n∑
r=1
r 6=i,r 6=ℓ
Grℓi,∗(µˆ∗, ξˆ).
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Therefore,
Qˆi,∗(µˆ∗, ξˆ)
=


1
(n− 1)(n − 2)
n∑
i=1
n∑
ℓ=i
ℓ 6=i
n∑
r=1
r 6=ℓ,r 6=i
∂Giℓr,∗(µˆ∗, ξ)
∂ξ⊤
∣∣∣∣
ξ=ξˆ


×
{
−
n∑
i=1
∂Si(ξ)
∂ξ⊤
∣∣∣∣
ξ=ξˆ
}−1
Si(ξˆ) (22)
+
1
(n− 1)(n− 2)
n∑
ℓ=1
ℓ 6=i
n∑
r=1
r 6=i,r 6=ℓ
{
Giℓr,∗(µˆ∗, ξˆ) +Gℓir,∗(µˆ∗, ξˆ) +Grℓi,∗(µˆ∗, ξˆ)
}
.
The quantity
n∑
i=1
∂Si(ξ)
∂ξ⊤
∣∣∣∣
ξ=ξˆ
could be obtained as the Hessian matrix of the log-likelihood
function at ξˆ. In order to compute
∂Giℓr,∗(µˆ∗, ξ)
∂ξ⊤
∣∣∣∣
ξ=ξˆ
, we have to get the derivatives
∂
∂ξ⊤
ρki(τ 0ρk ),
∂
∂ξ⊤
ρk(0)i(ξ),
∂
∂ξ⊤
π−1i (λ, τπ),
∂
∂ξ⊤
π10i(λ, τπ),
∂
∂ξ⊤
π01i(λ, τπ) and
∂
∂ξ⊤
π00i(λ, τπ).
In Section 2.3, we obtain
∂
∂λ1
π10i(λ, τπ) = π10i(1− π10i); ∂
∂λ2
π10i(λ, τπ) = 0;
∂
∂λ1
π01i(λ, τπ) = 0;
∂
∂λ2
π01i(λ, τπ) = π01i(1− π01i);
∂
∂λ1
π00i(λ, τπ) = 0;
∂
∂λ2
π00i(λ, τπ) = 0.
and
∂
∂τ⊤π
πd1d2i = Ui(1− πd1d2i)πd1d2i,
where (d1, d2) belongs to the set {(1, 0), (0, 1), (0, 0)}. Also, we have
∂
∂τ⊤ρ1
ρ1i(τρ) = Uiρ1i(1 − ρ1i); ∂
∂τ⊤ρ2
ρ1i(τρ) = −Uiρ1iρ2i;
∂
∂τ⊤ρ2
ρ2i(τρ) = Uiρ2i(1 − ρ2i); ∂
∂τ⊤ρ1
ρ2i(τρ) = −Uiρ1iρ2i.
Moreover,
∂
∂λs
π−1i (λ, τπ) = −Dsi
1− πi
πi
;
∂
∂τ⊤π
π−1i (λ, τπ) = −Ui
1− πi
πi
,
with s = 1, 2. Then, recall that
ρ1(0)i =
(1− π10i)ρ1i
(1 − π10i)ρ1i + (1− π01i)ρ2i + (1 − π00i)ρ3i
,
ρ2(0)i =
(1− π01i)ρ2i
(1 − π10i)ρ1i + (1− π01i)ρ2i + (1 − π00i)ρ3i
,
ρ3(0)i =
(1− π00i)ρ3i
(1 − π10i)ρ1i + (1− π01i)ρ2i + (1 − π00i)ρ3i
.
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After some algebra, we get
∂
∂λ1
ρ1(0)i(ξ) =
1
z2
[−π10i(1− π10i)ρ1i {(1− π01i)ρ2i + (1 − π00i)ρ3i}] ,
∂
∂λ2
ρ1(0)i(ξ) =
1
z2
ρ1iρ2iπ01i(1 − π01i)(1 − π10i),
∂
∂τ⊤π
ρ1(0)i(ξ) = −
Ui
z2
ρ1i(1− π10i)
{
ρ2i(1− π01i)(π10i − π01i)
+ ρ3i(1− π00i)(π10i − π00i)
}
,
∂
∂τ⊤ρ1
ρ1(0)i(ξ) =
Ui
z2
ρ1i(1− π10i) {ρ2i(1 − π01i) + ρ3i(1− π00i)} ,
∂
∂τ⊤ρ2
ρ1(0)i(ξ) = −
Ui
z2
ρ1iρ2i(1− π10i)(1− π01i).
Finally, we set z = (1− π10i)ρ1i + (1− π01i)ρ2i + (1 − π00i)ρ3i, and get
∂
∂λ1
ρ2(0)i(ξ) =
1
z2
ρ1iρ2iπ10i(1 − π10i)(1 − π01i),
∂
∂λ2
ρ2(0)i(ξ) =
1
z2
[−π01i(1− π01i)ρ2i {(1− π10i)ρ1i + (1 − π00i)ρ3i}] ,
∂
∂τ⊤π
ρ2(0)i(ξ) = −
Ui
z2
ρ2i(1− π01i)
{
ρ1i(1− π10i)(π01i − π10i)
+ ρ3i(1− π00i)(π01i − π00i)
}
,
∂
∂τ⊤ρ1
ρ2(0)i(ξ) = −
Ui
z2
ρ1iρ2i(1− π10i)(1− π01i),
∂
∂τ⊤ρ2
ρ2(0)i(ξ) =
Ui
z2
ρ2i(1− π01i) {ρ1i(1 − π10i) + ρ3i(1− π00i)} .
The derivative
∂
∂ξ⊤
ρ3(0)i(ξ) can be computed by using the fact that ρ3(0)i = 1 − ρ1(0)i −
ρ2(0)i.
Appendix 2
Here, we show that the estimating functions Giℓr,∗ are unbiased under the working disease
and verification models. Recall that ξ = (λ⊤, τ⊤π , τ⊤ρ )⊤.
– FI estimator. We have
E
{
Giℓr,FI(µ0, ξ0)
}
= E {ρ1i(τ 0ρ)ρ2ℓ(τ 0ρ)ρ3r(τ 0ρ)(Iiℓr − µ)}
= E {ρ1iρ2ℓρ3r(Iiℓr − µ0)} .
Hence, E
{
Giℓr,FI(µ0, ξ0)
}
= 0 from (13).
– MSI estimator. Consider E
{
Dki,MSI(ξ0)|Ti,Ai
}
. We have
E
{
Dki,MSI(ξ0)|Ti,Ai
}
= E
{
ViDki + (1 − Vi)ρk(0)i(ξ0)|Ti,Ai
}
= E
[
E
{
ViDki + (1− Vi)ρk(0)i(ξ0)|Ti,Ai, Vi
} |Ti,Ai]
= Pr(Vi = 1|Ti,Ai)E (Dki|Vi = 1, Ti,Ai)
+ Pr(Vi = 0|Ti,Ai)E
(
ρk(0)i(ξ0)|Vi = 0, Ti,Ai
)
= Pr(Vi = 1|Ti,Ai)Pr(Dki = 1|Vi = 1, Ti,Ai)
+ Pr(Vi = 0|Ti,Ai)Pr(Dki = 1|Vi = 0, Ti,Ai)
= Pr(Dki = 1|Ti,Ai) = ρki.
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Therefore,
E
{
Giℓr,MSI(µ0, ξ0)
}
= E
{
D1i,MSI(ξ0)D2ℓ,MSI(ξ0)D3r,MSI(ξ0) (Iiℓr − µ0)
}
= E
[
(Iiℓr − µ0)E
{
D1i,MSI(ξ0)|Ti,Ai
}
E
{
D2ℓ,MSI(ξ0)|Tℓ,Aℓ
}
× E{D3r,MSI(ξ0)|Tr ,Ar} ]
= E {ρ1iρ2ℓρ3r(Iiℓr − µ0)} .
– IPW estimator. In this case,
E
(
ViDkiπ
−1
i (ξ0)|Ti,Ai
)
= π−1i (ξ0)E (ViDki|Ti,Ai)
= π−1i (ξ0)E
{
DkiE (Vi|D1i,D2i, Ti,Ai)
∣∣Ti,Ai}
= π−1i E (πiDki|Ti,Ai) = ρki.
Thus,
E
{
Giℓr,IPW(µ0, ξ0)
}
= E
{
ViVℓVrD1iD2ℓD3r
πi(ξ0)πℓ(ξ0)πk(ξ0)
(Iiℓr − µ0)
}
= E
{
(Iiℓr − µ0)E(ViD1iπ−1i (ξ0)|Ti,Ai)E(VℓD2ℓπ−1ℓ (ξ0)|Tℓ,Aℓ)
× E(VrD3rπ−1r (ξ0)|Tr ,Ar)
}
= E {ρ1iρ2ℓρ3r(Iiℓr − µ0)} .
– PDR estimator.
E
{
Dki,PDR(ξ0)|Ti,Ai
}
= E
[
E
{
ViDki
πi(ξ0)
− ρk(0)i(ξ0)
(
Vi
πi(ξ0)
− 1
) ∣∣∣∣D1i,D2i, Ti,Ai
}∣∣∣∣Ti,Ai
]
= E
{
DkiE
(
Vi
πi(ξ0)
∣∣∣∣D1i,D2i, Ti,Ai
)
− ρk(0)i(ξ0)E
(
Vi
πi(ξ0)
− 1
∣∣∣∣D1i, D2i, Ti,Ai
) ∣∣∣∣Ti,Ai
}
= E(Dki|Ti,Ai) = ρki.
Hence,
E
{
Giℓr,PDR(µ0, ξ0)
}
= E
{
D1i,PDR(ξ0)D2ℓ,PDR(ξ0)D3r,PDR(ξ0) (Iiℓr − µ0)
}
= E
[
(Iiℓr − µ0)E
{
D1i,PDR(ξ0)|Ti,Ai
}
E
{
D2ℓ,PDR(ξ0)|Tℓ,Aℓ
}
× E{D3r,PDR(ξ0)|Tr,Ar} ]
= E {ρ1iρ2ℓρ3r(Iiℓr − µ0)} .
